Table 2.

Key exclusion criteria

Hepatitis B or C

Polycystic kidney disease or anatomical causes of chronic kidney disease

Type 1 diabetes mellitus

Severe hepatic impairment (Child–Pugh class C)

Severe comorbidities or history of disease or disorder that would put patient at risk, affect participation, or influence study results

Confirmed COVID-19 in the past 4 weeks or severe COVID-19 at any point

Ongoing use of any biologic drug and/or small molecule targeting the immune system

Use of drugs that affect serum creatinine concentration in the past month

Concomitant use of medications associated with torsades de pointes or strong inducers/inhibitors of cytochrome P450 3A4

Treatment with zileuton, leukotriene receptor antagonists (e.g., montelukast) or cilastatin in the past month

Treatment with simvastatin, lovastatin, or atorvastatin at doses more than 40 mg per day in the past month

Hypersensitivity to drugs with a chemical structure or class similar to that of AZD5718

Pregnancy or breastfeeding